Humacyte (NASDAQ:HUMA) Shares Up 7.5% – Should You Buy?

Humacyte, Inc. (NASDAQ:HUMA) shares traded up 7.5% on Friday . The company traded as high as $5.58 and last traded at $5.43. 1,147,588 shares were traded during mid-day trading, a decline of 51% from the average session volume of 2,327,989 shares. The stock had previously closed at $5.05.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on the stock. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. TD Cowen reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Cantor Fitzgerald reissued an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. BTIG Research reissued a “buy” rating and set a $10.00 price target on shares of Humacyte in a research note on Friday, October 18th. Finally, Piper Sandler set a $6.00 price target on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $10.00.

Humacyte Price Performance

The company has a quick ratio of 5.41, a current ratio of 5.41 and a debt-to-equity ratio of 0.61. The stock has a market cap of $643.30 million, a P/E ratio of -4.28 and a beta of 1.45. The firm’s fifty day moving average price is $5.57 and its 200-day moving average price is $6.08.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Tuesday, August 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). Analysts forecast that Humacyte, Inc. will post -1.09 earnings per share for the current year.

Insider Transactions at Humacyte

In other news, Director Kathleen Sebelius sold 5,182 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the transaction, the director now owns 40,276 shares in the company, valued at approximately $217,490.40. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, Director Kathleen Sebelius sold 5,182 shares of Humacyte stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $5.40, for a total value of $27,982.80. Following the sale, the director now owns 40,276 shares in the company, valued at $217,490.40. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Brady W. Dougan sold 352,112 shares of Humacyte stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now owns 3,677,262 shares in the company, valued at approximately $23,350,613.70. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,084,153 shares of company stock worth $6,869,996. Insiders own 11.20% of the company’s stock.

Institutional Trading of Humacyte

Several large investors have recently added to or reduced their stakes in HUMA. Millennium Management LLC boosted its holdings in Humacyte by 504.3% in the second quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock valued at $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Humacyte by 28.7% in the first quarter. Vanguard Group Inc. now owns 4,019,681 shares of the company’s stock valued at $12,501,000 after acquiring an additional 896,415 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Humacyte by 693.0% in the second quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock valued at $2,881,000 after acquiring an additional 524,600 shares in the last quarter. Marshall Wace LLP lifted its position in Humacyte by 3,301.5% during the second quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after buying an additional 450,031 shares during the period. Finally, Deerfield Management Company L.P. Series C purchased a new position in Humacyte during the second quarter valued at $1,550,000. Institutional investors own 44.71% of the company’s stock.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.